In pre-Neoadj-Chemo samples, the EGFR mutation rate was 55.6% (15/27) in adenocarcinoma, which is higher than measured in patients with squamous cell carcinoma (17.1% [6/35]). This evidence concerns the gene EGFR and squamous cell carcinoma.